Your browser doesn't support javascript.
loading
[Gualou Xiebai Banxia Decoction treats type 2 diabetes mellitus combined with acute myocardial infarction via chemerin/ CMKLR1/PPARα signaling pathway].
Wang, Lei; Guan, Shuai; Wu, Meng-Xue; Zhou, Hui; Zhao, Qi-Tao; Xun, Li-Ying.
  • Wang L; School of Pharmacy, Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
  • Guan S; School of Pharmacy, Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
  • Wu MX; School of Pharmacy, Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
  • Zhou H; School of Pharmacy, Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
  • Zhao QT; School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
  • Xun LY; School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine Ji'nan 250355, China.
Zhongguo Zhong Yao Za Zhi ; 49(6): 1579-1586, 2024 Mar.
Article en Zh | MEDLINE | ID: mdl-38621942
ABSTRACT
This study aims to investigate the effects of Gualou Xiebai Banxia Decoction(GXBD) on type 2 diabetes mellitus(T2DM) combined with acute myocardial infarction(AMI) in rats via chemerin/chemokine-like receptor 1(CMKLR1)/peroxisome proliferator-activated receptor α(PPARα) signaling pathway, and to explore the mechanism of GXBD in alleviating glucose and lipid metabolism disorders. The SD rats were randomized into control, model, positive control, and low-and high-dose GXBD groups. The rat model of T2DM was established by administration with high-fat emulsion(HFE) by gavage and intraperitoneal injection with streptozotocin, and then coronary artery ligation was performed to induce AMI. The control and model groups were administrated with the equal volume of normal saline, and other groups were administrated with corresponding drugs by gavage. Changes in relevant metabolic indicators were assessed by ELISA and biochemical assays, and the protein levels of chemerin, CMKLR1, and PPARα in the liver, abdominal fat, and heart were determined by Western blot. The results showed that GXBD alleviated the myocardial damage and reduced the levels of blood lipids, myocardial enzymes, and inflammatory cytokines, while it did not lead to significant changes in blood glucose. Compared with the model group, GXBD down-regulated the expression of chemerin in peripheral blood and up-regulated the expression of cyclic adenosine monophosphate(cAMP) and protein kinase A(PKA) in the liver. After treatment with GXBD, the protein levels of chemerin and CMKLR1 in the liver, abdominal fat, and heart were down-regulated, while the protein levels of PPARα in the liver and abdominal fat were up-regulated. In conclusion, GXBD significantly ameliorated the disorders of glycolipid metabolism in the T2DM-AMI model by regulating the chemerin/CMKLR1/PPARα signaling pathway to exert a protective effect on the damaged myocardium. This study provides a theoretical basis for further clinical study of GXBD against T2DM-AMI and is a manifestation of TCM treatment of phlegm and turbidity causing obstruction at the protein level.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Diabetes Mellitus Tipo 2 / Infarto del Miocardio Límite: Animals Idioma: Zh Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Diabetes Mellitus Tipo 2 / Infarto del Miocardio Límite: Animals Idioma: Zh Año: 2024 Tipo del documento: Article